# IBI310

Source: https://onco.cc/drugs/ibi310/  
OnCo record `ibi310` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBI310 is an experimental investigational agent whose form is not stated in the registry from Innovent Biopharmaceutical Technology (Hangzhou) in phase 3 trials for hepatocellular carcinoma, with its target not yet stated publicly.

## Summary

IBI310 is an investigational agent whose form is not stated in the registry developed by Innovent Biopharmaceutical Technology (Hangzhou). Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07490262 (A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment), in hepatocellular carcinoma. The largest, NCT07490262, plans to enrol 680 participants with primary completion expected 2027-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody (anti-CTLA-4, per the sponsor's pipeline page; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of IBI310: https://clinicaltrials.gov/search?intr=IBI310

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- trials: [A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment](https://onco.cc/trials/nct07490262/)

---
JSON: https://onco.cc/api/v1/entities/ibi310.json